Shots:
- The CHMP has recommended Itovebi + Ibrance & fulvestrant as a 1L therapy for adults with PIK3CA-mutated, HR+/HER2- locally advanced or metastatic breast cancer recurring on or within 12mos. of adj. endocrine therapy, based on the P-III (INAVO120) trial
- Trial (n=325) assessed the regimen vs PBO + Ibrance & fulvestrant, improved PFS (1EP) by 57% (mPFS: 15 vs 7.3mos.), with consistent benefit across subgroups; a meaningful OS benefit was observed, with full OS data to be shared at ASCO 2025
- Additionally, Roche is evaluating Itovebi in 3 more P-III trials (INAVO121, INAVO122 & INAVO123) for the same indication in various combinations
Ref: Roche| Image: Roche| Press Release
Related News:- Roche Reports the US FDA’s Approval of Susvimo to Treat Diabetic Retinopathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
